Royalty Pharma plc Other Non-Current Liabilities
Royalty Pharma plc (RPRX) had Other Non-Current Liabilities of $108.02 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-05
- 2026-06-30: Other Liabilities, Noncurrent $108.02M.
- 2026-03-31: Other Liabilities, Noncurrent $117.78M.
- 2025-12-31: Other Liabilities, Noncurrent $120.84M.
- 2025-09-30: Other Liabilities, Noncurrent $126.94M.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2026-06-30 | $108.02M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $117.78M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $120.84M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $126.94M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $143.33M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $17.90M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $12.08M 10-K · filed 2026-02-11 |
| 2024-09-30 | $5.58M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $27.04M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.22M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $900.00K 10-K · filed 2025-02-12 |
| 2022-12-31 | $2.50M 10-K · filed 2024-02-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-15 |
| 2020-09-30 | $110.00M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $110.00M 10-Q · filed 2020-08-12 |
| 2019-12-31 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |